Cencora, Inc. (NYSE: COR) Stock Competitors & Peer Comparison
See COR's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for COR and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| COR | $300.25 | -2.39% | 58.4B | 17.51 | $17.15 | +0.80% |
| MCK | $853.81 | -1.27% | 100.1B | 20.94 | $40.82 | +0.40% |
| CAH | $222.50 | -0.63% | 52.1B | 21.34 | $10.43 | +0.91% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $83.97 | -1.18% | 9.6B | 15.81 | $5.31 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +2.49% |
| AHG | $0.90 | +30.25% | 781.5M | -4.29 | -$0.21 | N/A |
| OMI | $2.68 | +8.94% | 207.1M | -0.47 | -$5.69 | N/A |
| EMPG | $17.36 | +0.00% | 143M | 192.89 | $0.09 | N/A |
| HX | $2.24 | -4.27% | 53.4M | -1.84 | -$1.22 | N/A |
Stock Comparison
McKesson Corporation (NYSE: MCK)
COR vs MCK Comparison October 2026
Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 58.4B. In comparison, MCK has a market cap of 100.1B. Regarding current trading prices, COR is priced at $300.25 on the NYSE, while MCK trades at $853.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.51, whereas MCK's P/E ratio is 20.94. In terms of profitability, COR's ROE is +1.06%, compared to MCK's ROE of -1.94%. Regarding short-term risk, COR is more volatile compared to MCK. This indicates higher risk in terms of short-term price fluctuations for COR.Check MCK's competition here
Cardinal Health, Inc. (NYSE: CAH)
COR vs CAH Comparison October 2026
Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 58.4B. In comparison, CAH has a market cap of 52.1B. Regarding current trading prices, COR is priced at $300.25 on the NYSE, while CAH trades at $222.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.51, whereas CAH's P/E ratio is 21.34. In terms of profitability, COR's ROE is +1.06%, compared to CAH's ROE of -0.60%. Regarding short-term risk, COR is more volatile compared to CAH. This indicates higher risk in terms of short-term price fluctuations for COR.Check CAH's competition here
AmerisourceBergen Corporation (NYSE: ABC)
COR vs ABC Comparison October 2026
Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 58.4B. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, COR is priced at $300.25 on the NYSE, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.51, whereas ABC's P/E ratio is 21.92. In terms of profitability, COR's ROE is +1.06%, compared to ABC's ROE of +1.06%. Regarding short-term risk, COR is more volatile compared to ABC. This indicates higher risk in terms of short-term price fluctuations for COR.Check ABC's competition here
Henry Schein, Inc. (NASDAQ: HSIC)
COR vs HSIC Comparison October 2026
Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 58.4B. In comparison, HSIC has a market cap of 9.6B. Regarding current trading prices, COR is priced at $300.25 on the NYSE, while HSIC trades at $83.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.51, whereas HSIC's P/E ratio is 15.81. In terms of profitability, COR's ROE is +1.06%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, COR is more volatile compared to HSIC. This indicates higher risk in terms of short-term price fluctuations for COR.Check HSIC's competition here
Patterson Companies, Inc. (NASDAQ: PDCO)
COR vs PDCO Comparison October 2026
Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 58.4B. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, COR is priced at $300.25 on the NYSE, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.51, whereas PDCO's P/E ratio is 20.48. In terms of profitability, COR's ROE is +1.06%, compared to PDCO's ROE of +0.18%. Regarding short-term risk, COR is more volatile compared to PDCO. This indicates higher risk in terms of short-term price fluctuations for COR.Check PDCO's competition here
Akso Health Group (NASDAQ: AHG)
COR vs AHG Comparison October 2026
Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 58.4B. In comparison, AHG has a market cap of 781.5M. Regarding current trading prices, COR is priced at $300.25 on the NYSE, while AHG trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.51, whereas AHG's P/E ratio is -4.29. In terms of profitability, COR's ROE is +1.06%, compared to AHG's ROE of -0.50%. Regarding short-term risk, COR is less volatile compared to AHG. This indicates lower risk in terms of short-term price fluctuations for COR.Check AHG's competition here
Owens & Minor, Inc. (NYSE: OMI)
COR vs OMI Comparison October 2026
Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 58.4B. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, COR is priced at $300.25 on the NYSE, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.51, whereas OMI's P/E ratio is -0.47. In terms of profitability, COR's ROE is +1.06%, compared to OMI's ROE of +0.63%. Regarding short-term risk, COR is less volatile compared to OMI. This indicates lower risk in terms of short-term price fluctuations for COR.Check OMI's competition here
Empro Group Inc. Ordinary shares (NASDAQ: EMPG)
COR vs EMPG Comparison October 2026
Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 58.4B. In comparison, EMPG has a market cap of 143M. Regarding current trading prices, COR is priced at $300.25 on the NYSE, while EMPG trades at $17.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.51, whereas EMPG's P/E ratio is 192.89. In terms of profitability, COR's ROE is +1.06%, compared to EMPG's ROE of +0.66%. Regarding short-term risk, COR is more volatile compared to EMPG. This indicates higher risk in terms of short-term price fluctuations for COR.Check EMPG's competition here
Akso Health Group (NASDAQ: HX)
COR vs HX Comparison October 2026
Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 58.4B. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, COR is priced at $300.25 on the NYSE, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.51, whereas HX's P/E ratio is -1.84. In terms of profitability, COR's ROE is +1.06%, compared to HX's ROE of -1.07%. Regarding short-term risk, COR is less volatile compared to HX. This indicates lower risk in terms of short-term price fluctuations for COR.Check HX's competition here
Accendra Health, Inc. (NYSE: ACH)
COR vs ACH Comparison October 2026
Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 58.4B. In comparison, ACH has a market cap of 43.9M. Regarding current trading prices, COR is priced at $300.25 on the NYSE, while ACH trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.51, whereas ACH's P/E ratio is 0.84. In terms of profitability, COR's ROE is +1.06%, compared to ACH's ROE of +0.63%. Regarding short-term risk, COR is less volatile compared to ACH. This indicates lower risk in terms of short-term price fluctuations for COR.Check ACH's competition here
111, Inc. (NASDAQ: YI)
COR vs YI Comparison October 2026
Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 58.4B. In comparison, YI has a market cap of 29.9M. Regarding current trading prices, COR is priced at $300.25 on the NYSE, while YI trades at $3.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.51, whereas YI's P/E ratio is -2.07. In terms of profitability, COR's ROE is +1.06%, compared to YI's ROE of +0.24%. Regarding short-term risk, COR is less volatile compared to YI. This indicates lower risk in terms of short-term price fluctuations for COR.Check YI's competition here
Wellgistics Health, Inc. (NASDAQ: WGRX)
COR vs WGRX Comparison October 2026
Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 58.4B. In comparison, WGRX has a market cap of 8.7M. Regarding current trading prices, COR is priced at $300.25 on the NYSE, while WGRX trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.51, whereas WGRX's P/E ratio is -0.33. In terms of profitability, COR's ROE is +1.06%, compared to WGRX's ROE of +8.78%. Regarding short-term risk, COR is less volatile compared to WGRX. This indicates lower risk in terms of short-term price fluctuations for COR.Check WGRX's competition here
DataMEDS AI, Inc. (NASDAQ: MEDS)
COR vs MEDS Comparison October 2026
Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 58.4B. In comparison, MEDS has a market cap of 8.4M. Regarding current trading prices, COR is priced at $300.25 on the NYSE, while MEDS trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.51, whereas MEDS's P/E ratio is N/A. In terms of profitability, COR's ROE is +1.06%, compared to MEDS's ROE of +8.78%. Regarding short-term risk, COR is less volatile compared to MEDS. This indicates lower risk in terms of short-term price fluctuations for COR.Check MEDS's competition here
Zynex, Inc. (NASDAQ: ZYXI)
COR vs ZYXI Comparison October 2026
Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 58.4B. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, COR is priced at $300.25 on the NYSE, while ZYXI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.51, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, COR's ROE is +1.06%, compared to ZYXI's ROE of +11.38%. Regarding short-term risk, COR is more volatile compared to ZYXI. This indicates higher risk in terms of short-term price fluctuations for COR.Check ZYXI's competition here
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD)
COR vs HKPD Comparison October 2026
Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 58.4B. In comparison, HKPD has a market cap of 1.2M. Regarding current trading prices, COR is priced at $300.25 on the NYSE, while HKPD trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.51, whereas HKPD's P/E ratio is -1.60. In terms of profitability, COR's ROE is +1.06%, compared to HKPD's ROE of -0.15%. Regarding short-term risk, COR is less volatile compared to HKPD. This indicates lower risk in terms of short-term price fluctuations for COR.Check HKPD's competition here
Synergy CHC Corp. (NASDAQ: SNYR)
COR vs SNYR Comparison October 2026
Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 58.4B. In comparison, SNYR has a market cap of 941.8K. Regarding current trading prices, COR is priced at $300.25 on the NYSE, while SNYR trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.51, whereas SNYR's P/E ratio is -0.06. In terms of profitability, COR's ROE is +1.06%, compared to SNYR's ROE of +0.91%. Regarding short-term risk, COR is less volatile compared to SNYR. This indicates lower risk in terms of short-term price fluctuations for COR.Check SNYR's competition here
Ridgetech, Inc. (NASDAQ: RDGT)
COR vs RDGT Comparison October 2026
Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 58.4B. In comparison, RDGT has a market cap of 741.7K. Regarding current trading prices, COR is priced at $300.25 on the NYSE, while RDGT trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.51, whereas RDGT's P/E ratio is -0.02. In terms of profitability, COR's ROE is +1.06%, compared to RDGT's ROE of -0.04%. Regarding short-term risk, COR is less volatile compared to RDGT. This indicates lower risk in terms of short-term price fluctuations for COR.Check RDGT's competition here
Covetrus, Inc. (NASDAQ: CVET)
COR vs CVET Comparison October 2026
Cencora, Inc. (NYSE: COR) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 58.4B. In comparison, CVET has a market cap of 0. Regarding current trading prices, COR is priced at $300.25 on the NYSE, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 17.51, whereas CVET's P/E ratio is -69.97. In terms of profitability, COR's ROE is +1.06%, compared to CVET's ROE of -0.06%. Regarding short-term risk, COR is more volatile compared to CVET. This indicates higher risk in terms of short-term price fluctuations for COR.Check CVET's competition here